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Abstract 
Purpose: To formulate and characterize a gastroretentive floating drug delivery system for diltiazem 
hydrochloride using psyllium husk and sodium alginate as natural herbal carriers to improve the 
therapeutic effect of the drug in cardiac patients. 
Methods: Floating microparticles containing diltiazem hydrochloride were prepared by the orifice ionic 
gelation technique. Various physicochemical properties of the floating microspheres were characterized, 
including drug content, particle size, surface morphology, in vitro drug release, and in vivo 
antihypertensive effect. 
Results: The diltiazem hydrochloride microparticles exhibited a high drug content ranging from 63.23 ± 
1.14 to 85.56 % ± 1.14 %. The particle size was 891.40  ±  2.14, 928.40  ±  1.79, 900.65  ±  2.22, and 
1345.40  ±  1.36 μm (p < 0.05 compared to blank microspheres for formulations FDD1, FDD2, FDD3, 
and FFD4), respectively. Scanning electron microscopy showed that all the formulations had a smooth 
spherical surface with little pores and few cracks. The maximum floatability value was 83.11 % ± 3.18 % 
for FDD1. All of the formulations showed good in vitro drug release profiles, with a maximum release of 
87.4 % of the drug at the end of 12 hours. The in vivo antihypertensive effects of the microparticles in 
human subjects were significant (p < 0.05 compared to normal controls), with a reduction in diastolic 
blood pressure from 120 to 78 mmHg at the end of 4 hours compared to diltiazem sustained-release 
tablets. 
Conclusion: Psyllium husk and sodium alginate-based microspheres can be suitably prepared for the 
controlled delivery of diltiazem hydrochloride to cardiac patients. However, further study is required to 
develop the delivery system. 
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Herbal-based drug delivery systems have long 
been used in folk medicine, and herbal 
medicines of natural origin show good 
therapeutic activity with minimal side effects. The 
World Health Organization estimates that 80 % 
of the world’s population currently uses herbal 
medicines for primary health care. Thus, 
researchers have begun to focus on herbal drugs 
and the use of materials of herbal origin. Herbal 
medicines have many advantages over 
traditional medicines, including a lower risk of 
side effects, lower cost, and widespread 
availability [1,2]. 
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Gastroretention is the most feasible approach for 
achieving prolonged, predictable, and controlled 
drug delivery in the gastrointestinal tract. These 
systems have a lower density than gastric fluid 
and remain buoyant in the stomach without 
affecting gastric emptying for prolonged periods 
[3-6]. 
 
Psyllium husk is a source of mucilaginous fiber 
obtained from the dried seed coats of Plantago 
ovata. It forms a gel upon contact with water, and 
its swelling behavior makes it suitable for use as 
a carrier for diltiazem hydrochloride (HCl) 
microparticles [7,8]. 
 
Diltiazem HCl is a calcium channel blocker that 
inhibits the influx of calcium (Ca2+) ions during 
membrane depolarization in cardiac and vascular 
smooth muscle. It is effective in the treatment of 
hypertension and angina pectoris due to its 
cardiac effects. It has 40% oral bioavailability [9], 
and so requires frequent dosing to avoid these 
drawbacks. The administration of conventional 
diltiazem HCl tablets causes fluctuations in the 
plasma drug level resulting in side effects due to 
reduced drug concentrations at receptor sites. 
Furthermore, the maintenance of a constant 
plasma concentration of cardiac vascular drugs 
is important to ensure the designed therapeutic 
response; as the half-life of diltiazem HCl is 3  –  
4 h, multiple doses of the drug are needed to 
maintain a constant plasma concentration for a 
good therapeutic response and to improve 
patient compliance [10-13]. 
 
The present study was performed to develop a 
gastroretentive floating drug delivery system for 
diltiazem HCl using psyllium husk and sodium 
alginate as natural herbal carriers to achieve 






Diltiazem HCl was obtained from Sigma-Aldrich 
(St. Louis, MO). Psyllium husk was obtained from 
the Department of Traditional Chinese Medicine, 
Medical College of Shihezi University, Xinjiang, 
China. All other reagents were of analytical grade 
or higher and obtained commercially. 
 
Preparation of diltiazem HCl microparticles 
 
Floating microparticles containing diltiazem HCl 
were prepared by the orifice ionic gelation 
technique using the composition shown in Table 
1. 
 













 FDD1 100 200 150 
 FDD2 100 100 150 
 FDD3 100 150 100 
 FDD4  100 250 50 
 
Sodium alginate and psyllium husk were 
dissolved in purified water to form a firm gel, and 
the gas-forming agent sodium carbonate was 
dispersed in the purified water to form a 
homogeneous polymer mixture. The drug was 
added to the polymeric solution and mixed 
thoroughly with a magnetic stirrer to form a 
homogeneous mixture. Gelation medium 
containing 2 % calcium chloride in glacial acetic 
acid was prepared. The homogenous polymer 
solution was extruded into the gelation medium 
using a 21-G needle. The distance between the 
tip of the needle and surface of the gelation 
medium was maintained at 10 cm. The 
mechanical strength of the microparticles was 
improved by gentle stirring for 30 minutes at 
room temperature. The prepared microparticles 
were collected, washed twice with distilled water, 
dried at room temperature for 24 hours, and 
stored in desiccators [14]. 
 
Assessment of microparticle size and shape  
 
The size of the microparticles was determined 
using an optical microscope fitted with an ocular 
and stage micrometer. Scanning electron 
microscopy (SEM) was performed to determine 
the surface morphology of the formed 
microparticles. The preparations were mounted 
directly onto the sample stub and coated with 
gold film (~200 nm) under reduced pressure 
(0.130 Pa) (JSM-1600; JEOL Ltd., Tokyo, 
Japan). 
 
Determination of drug content  
 
The drug content was determined by dissolving a 
50 mg equivalent of diltiazem HCl microspheres 
in 100 mL of 0.1 N HCl. 
 
This solution was then stirred on a magnetic 
stirrer for 24 hours and filtered. Next, the 
samples were withdrawn, filtered, diluted 
appropriately, and measured 
spectrophotometrically at 243 nm to determine 
the drug content.  
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Evaluation of bulk density 
 
The bulk density of the prepared gastroretentive 
floating microspheres was determined using a 




In vitro floating behavior studies were performed 
by placing 50 microparticles in 50 mL glass 
flasks. To exclude floating due to non-wet 
surfaces, an additional 50 mL of 0.1 N HCl 
containing 0.02 % w/v Tween 20 was added 
followed by horizontal shaking (37 °C, 75 rpm). 
The flasks were allowed to stand for 5 minutes 
without agitation, and the particles were counted. 
This procedure was repeated after 2, 4, 6, and 8 
hours. The percentage of floating microspheres 
was calculated using the following equation.  
 
In vitro drug release studies 
 
The in vitro release profile of the microspheres 
was evaluated using an eight-station USP 
dissolution test apparatus with 900 mL of acid 
buffer (pH 1.2) as the dissolution medium. It 
was maintained at 37 ± 0.5 °C at 50 rpm. 
Aliquots of an accurately weighed 100 mg 
equivalent of drug microspheres were added 
and dissolution was performed for 2.5 h. 
Samples (5 mL each) were withdrawn every 
30 minutes and replaced with an equal volume 
of fresh medium to maintain sink conditions. The 
samples were filtered, diluted appropriately, 
and analyzed spectrophotometrically for drug 
release at 243 nm. The dissolution medium 
was then replaced by 900 mL of phosphate 
buffer (pH 6.8) maintained at 37 °C  ±  0.5 °C 
at 50 rpm. This study was continued for 12 h. 
 
In vivo antihypertensive effect 
 
This study was conducted in accordance with the 
International Ethical Guidelines for Biomedical 
Research Involving Human Subjects [15]. The 
study was approved by the ethics committee of 
Medical College of Shihezi University (approval 
no. TEK-1345523). The antihypertensive effect 
was studied in 60 hypertensive men aged 35 – 
45 years with a diastolic pressure of 100 – 120 
mmHg.  Each subject provided written consent 
prior to participation. The exclusion criteria 
included patients with obesity, patients on 
multidrug therapy, liver or renal failure patients, 
and smokers. The in vivo antihypertensive effect 
of the selected formulation (50 mg of diltiazem 
containing an equivalent amount of microspheres 
in capsules of size 000) was examined in 30 
hypertensive men in comparison to a group of 30 
hypertensive men administered oral diltiazem 
tablets (10 mg). The patients were administered 
the sample preparation (with about 250 mL of 
water) or tablets in the morning after an overnight 
fast. The diastolic blood pressure was measured 




The results are expressed as mean ± standard 
deviation (SD) and were analyzed by Student’s t-
test. The level of statistical significance was set 




The drug content of the microsphere formulations 
are show in Table 2. The bulk densities of all 
formulations indicate good flow properties and 
floatability. The bulk density was between 0.177 
± 0.0322 and 0.232 ± 0.0232 g/mL. 
 
SEM showed that all of the formulations had a 
smooth spherical surface with little porosity and 
few cracks (Figure 1A to Figure 1D). 
 
A buoyancy study showed an optimum floating 
time of more than 8 hours for the formulations. 
The percentage buoyancy was 83.11 ± 3.18, 
76.34 ± 1.15, 79.99  ± 1.89  and 75.22 ± 1.44 % 
for FDD1, FDD2, FDD3, and FFD4, respectively. 
 
At the end of 12 h, the percentage of the drug 
that had been released was 87.4, 80.3, 83.1 
and 75.2 % for FDDD1, FDD2, FDD3, and 
FDD4, respectively (Figure 2). 
 
The in vivo antihypertensive results showed that 
the diastolic blood pressure decreased from 120 
to 78 mmHg at the end of 4 hours and 
maintained this level for 10 hours. On the other 
hand, diltiazem tablets reduced the patients’  
 
            Table 2: Physical characteristics of the diltiazem HCl microspheres  
 







FDD1 85.56 ± 1.14 891.40 ± 2.14a 0.232 ± 0.0232a 83.11 ± 3.18a 
FDD2 80.12 ± 1.24 928.40 ± 1.79a 0.210 ± 0.0322a 76.34 ± 1.15a 
FDD3 81.77 ± 3.11 900.65 ± 2.22a 0.179 ± 0.0172a 79.99 ± 1.89a 
FDD4 63.23 ± 1.14 1345.40 ± 1.36a 0.177 ± 0.0322a 75.22 ± 1.44a 
            *All values are expressed as means ± SD, n = 3; ap < 0.05 compared to blank microspheres 
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Figure 1: Scanning electron micrographs of floating 
microspheres: (1A) FDD1 (50×); (1B) FDD2 (25×); (1C) 
FDD3 (50×); and (1D) FDD4 (50×) 
 
diastolic pressure from 110 to 97 mm Hg at the 




Prolonged release of diltiazem from floating 
microparticles not only increased the therapeutic 
efficacy and patient compliance but also 
produced a more reliable plasma drug profile as 
compared to diltiazem tablets. 
 
 
Figure 2: In vitro drug release profiles for floating 
microspheres of diltiazem: F1 (–♦–), F2 (–□–), F3 (–▲), 
and F4 (–○–) 
 
 
Figure 3: In vivo antihypertensive effect of floating 
microsphere formulation FDD2 (–♦–) vs. conventional 
tablets (–■–) 
 
The particles ranged in size from 891.40 ± 2.14 
to 1345.40 ± 1.36 μm. The mean particle size 
varied significantly according to the different 
proportions of polymers used, which may have 
been due to differences in the viscosity of the 
polymer solution [16-20]. The particles in 
formulation FDD1 (containing a greater quantity 
of psyllium husk) were larger than those in the 
other formulations. This is not surprising since 
psyllium husk contributed significantly to the 
viscosity of the polymer solution. Previous 
studies also suggested that psyllium husk-based 
extended release drug preparations were 
effective in delivering the loaded drugs. An 
increase in psyllium husk concentration was 
shown to increase both the viscosity of the 
dispersed phase and the entrapment efficiency of 
microparticles [21-23]. 
 
All of the formulations showed significant drug 
loading, which may have been due to strong 
intermolecular bonding between the polymer 
and drug. Thus, the drug was uniformly 
distributed and an optimum drug 
concentration was obtained at the site of 
action. 
Zhou et al 
Trop J Pharm Res, June 2017; 16(6): 1243  
 
Determinations of bulk density are important with 
respect to floating drug delivery to ensure good 
flow properties and floatability. Previous studies 
also suggested the floating behavior of diltiazem 
microspheres (maximum floatability: 85.31 %). 
As the size of the microparticles increased, the 
bulk density decreased due to an increase in 
space between the molecules. 
 
In vitro buoyancy testing showed a maximum 
percent buoyancy of 83.11 ± 3.18 % at the end of 
8 hours. The good floating behavior of the 
particles was attributed to the low density and 
hollow nature of the microparticles. Previous 
studies also suggested that hollow cavities in 
microparticles occurred due to the production of 
air bubbles during their formulation. 
 
The formulations yielded a gradual and more 
sustained release of the drug over the study 
period. These results show that diltiazem-loaded 
microparticles could be used once daily for the 
treatment of arrhythmia, angina, and other 
cardiac disorders. In the first few hours, the 
microspheres provided an initial burst of release 
due to rapid dissolution of the drug from the 
surface of the microparticles [24,25]. This can be 
considered as the loading dose, with the rest of 
the drug release considered as the maintenance 
dose. The release kinetics indicates that the drug 
release from the formulations followed a matrix 
diffusion process. Based on the obtained particle 
size, morphology, drug content, in vitro release, 
and release kinetics, formulation FDD1 was 
selected for testing of its in vivo antihypertensive 
effects. The results confirm that FDD1 efficiently 
reduced the patients’ diastolic blood pressure 
from 120 to 78 mmHg at the end of 4 h, in 
comparison with diltiazem tablets. In vitro drug 
release, buoyancy and in vivo antihypertensive 
data indicate that formulation FDD1 would reside 
in the gastric region for a long period and thus 




Psyllium husk and sodium alginate have been 
used as natural herbal carriers for formulations of 
diltiazem floating microparticles to achieve drug 
release in the treatment of hypertension. The 
floating microparticles display good floating, 
suitable in vitro drug release profile and good in 
vivo antihypertensive effects. Thus, the 
formulation has potential for use as a drug 
delivery system, but additional studies are 
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